meta|Evidence - COVID-19
click on circles to display study description...
Comirnaty (tozinameran - Pfizer/BIONTECH) (n=-9) vs. control (n=-9)
- risk of bias NA
mRNA BNT162b2
COVID-19 prophylaxis (excluding children)
Comirnaty (tozinameran - Pfizer/BIONTECH) (n=21720) vs. placebo (n=21728)
randomized controlled trial some concerns about risk of bias
BNT162b2
two doses, 21 days apart, of BNT162b2 vaccine candidate (30 μg per dose)
placebo
COVID-19 prophylaxis (excluding children)
Adults 16 years of age or older who were healthy or had stable chronic medical conditions, including but not limited to human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection. Key exclusion criteria included a medical history of Covid-19, treatment with immunosuppressive therapy, or diagnosis with an immunocompromising condition
double-blind
152 sites worldwide
phase1/2/3 study (seamless)
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=15181) vs. placebo (n=15170)
randomized controlled trial some concerns about risk of bias
mRNA-1273 vaccine
100 μg of mRNA-1273 two-dose schedule given one month apart
placebo
saline placebo two-dose schedule given one month apart
COVID-19 prophylaxis (excluding children)
double blind
100 centres, USA
Randomization was stratified based on age and the presence or absence of risk factors for severe illness for COVID-19
Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=189) vs. placebo (n=186)
randomized controlled trial risk of bias NA
mRNA-1273 100µg
placebo
COVID-19 prophylaxis (excluding children)
double-blind
phase 2a
powered by vis.js Network